Atea Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Atea Pharmaceuticalsの CEO はJean-Pierre Sommadossiで、 Jul2012年に任命され、 の在任期間は 13.92年です。 の年間総報酬は$ 3.40Mで、 20.7%給与と79.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の8.29%を直接所有しており、その価値は$ 28.66M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と5.8年です。
主要情報
Jean-Pierre Sommadossi
最高経営責任者
US$3.4m
報酬総額
| CEO給与比率 | 20.67% |
| CEO在任期間 | 13.9yrs |
| CEOの所有権 | 8.3% |
| 経営陣の平均在職期間 | 5.8yrs |
| 取締役会の平均在任期間 | 5.8yrs |
経営陣の近況
Recent updates
Seeking Alpha • May 29
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Summary Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR’s BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR’s $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie. Failure in both Phase 3 studies threatens AVIR’s survival, while success could trigger a share price spike or potential acquisition interest. Read the full article on Seeking Alpha
新しいナラティブ • May 15
Hepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?分析記事 • May 14
We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
新しいナラティブ • Mar 19
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 05
Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biotechnology company focused on developing oral direct acting antivirals for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Sep 26
Atea wins FDA Fast Track status for dengue treatment
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosquito-borne virus in the world, affecting an estimated up to 400M people annually. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. Developed using AVIR’s purine nucleotide prodrug platform, AT-752 is currently undergoing two proof-of-concept studies for dengue, with data expected at the end of the year. Read more on upcoming milestones for AVIR as outlined by the management in August.Seeking Alpha • Aug 08
Atea Pharmaceuticals Q2 2022 Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.49 (-2550.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward.分析記事 • May 13
Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 16x, you may...分析記事 • Jan 05
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Today is shaping up negative for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders, with the analysts delivering...分析記事 • Nov 25
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
The latest analyst coverage could presage a bad day for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), with the analysts...分析記事 • Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.分析記事 • Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.Seeking Alpha • Oct 20
Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Atea Pharmaceuticals posted underwhelming data from a Phase 2 trial of its COVID antiviral therapy AT-527 on Oct. 19, causing its stock price to fall by 66%. The drug failed to meet its endpoint of reduction of the SARS-Cov-2 virus compared to placebo in a subset of patients - around two-thirds of whom were low risk. Atea has a similar mechanism of action to Merck's Molnupiravir, which looks likely to win Emergency Approval for mild-to-moderate COVID-19 patients who are at risk for progressing to severe COVID. If Atea management has used only unvaccinated patients with a serious underlying health issue, as Merck did, the outcome of its MOONSONG trial may have been different. As such, Atea may be able to alter pivotal trial protocols and still make it to market - although yesterday's data means that will not happen for at least another year, by which time, it may be too late.CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$170m |
| Dec 31 2025 | US$3m | US$703k | -US$158m |
| Sep 30 2025 | n/a | n/a | -US$147m |
| Jun 30 2025 | n/a | n/a | -US$136m |
| Mar 31 2025 | n/a | n/a | -US$139m |
| Dec 31 2024 | US$4m | US$703k | -US$168m |
| Sep 30 2024 | n/a | n/a | -US$174m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$164m |
| Dec 31 2023 | US$6m | US$683k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$131m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$6m | US$650k | -US$116m |
| Sep 30 2022 | n/a | n/a | US$36m |
| Jun 30 2022 | n/a | n/a | US$16m |
| Mar 31 2022 | n/a | n/a | US$48m |
| Dec 31 2021 | US$34m | US$650k | US$121m |
| Sep 30 2021 | n/a | n/a | US$25m |
| Jun 30 2021 | n/a | n/a | US$35m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$3m | US$437k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$811k | US$400k | -US$14m |
報酬と市場: Jean-Pierreの 総報酬 ($USD 3.40M ) は、 US市場 ($USD 2.63M ) の同規模の企業の平均を上回っています。
報酬と収益: Jean-Pierreの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Jean-Pierre Sommadossi (70 yo)
13.9yrs
在職期間
US$3,403,752
報酬
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 13.9yrs | US$3.40m | 8.29% $ 28.7m | |
| CFO, Executive VP of Legal & Secretary | 12.5yrs | US$1.69m | 1.03% $ 3.6m | |
| Chief Commercial Officer | 7.7yrs | US$1.22m | 0.21% $ 713.2k | |
| Chief Development Officer | 5.8yrs | US$1.77m | 0.16% $ 551.5k | |
| Chief Medical Officer | 5.8yrs | US$1.59m | 0.12% $ 415.1k | |
| Executive VP of Finance & Chief Accounting Officer | 4.4yrs | US$1.52m | 0.099% $ 342.7k | |
| Senior Vice President of Investor Relations & Corporate Communications | 5.4yrs | データなし | データなし | |
| Executive Vice President of Chemistry | no data | データなし | データなし | |
| Executive Vice President of Early Stage Development | no data | データなし | データなし | |
| Executive VP of Clinical Sciences & Project Management | 6.4yrs | データなし | データなし | |
| Executive Vice President of Regulatory Affairs | 5.4yrs | データなし | データなし | |
| Executive Vice President of Preclinical Development | 4.3yrs | データなし | データなし |
5.8yrs
平均在職期間
63.5yo
平均年齢
経験豊富な経営陣: AVIRの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 13.9yrs | US$3.40m | 8.29% $ 28.7m | |
| Independent Director | 1.3yrs | US$415.33k | 0.057% $ 197.5k | |
| Independent Director | 5.7yrs | US$256.90k | 0.078% $ 271.1k | |
| Independent Director | 11.8yrs | US$249.40k | 0.14% $ 487.1k | |
| Lead Independent Director | 6.8yrs | US$282.90k | 0.63% $ 2.2m | |
| Independent Director | 11.6yrs | US$249.40k | 0.12% $ 411.3k | |
| Independent Director | 5.8yrs | US$251.90k | 0.12% $ 398.1k | |
| Independent Director | 5.1yrs | US$366.90k | 0.078% $ 271.1k | |
| Independent Director | 1yr | US$407.11k | 0% $ 0 |
5.8yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: AVIRの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/09 07:16 |
| 終値 | 2026/06/09 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Atea Pharmaceuticals, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| Eric Joseph | J.P. Morgan |
| Matthew Harrison | Morgan Stanley |
| Maxwell Skor | Morgan Stanley |